1,876 results on '"Kvien, Tore K"'
Search Results
552. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report
553. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
554. Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis:Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity
555. Brief Report: No Excess Risks in Offspring With Paternal Preconception Exposure to Disease-Modifying Antirheumatic Drugs
556. The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases
557. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study
558. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
559. A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
560. Obesity and osteoarthritis in knee, hip and/or hand: An epidemiological study in the general population with 10 years follow-up
561. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein
562. 249 - Biosimilar Infliximab (CT-P13) is not Inferior to Originator Infliximab: Explorative IBD Subgroup-Analyses in Crohn's Disease and Ulcerative Colitis from the Nor-Switch Trial
563. EULAR 75-year anniversary: commentaries on key ARD papers from 1947.
564. Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort.
565. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients.
566. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
567. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
568. Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis.
569. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
570. Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti- cyclic citrullinated peptide and rheumatoid factor.
571. Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis
572. Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study
573. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
574. MRI findings predict radiographic progression and development of erosions in hand osteoarthritis
575. The Burden of Disease in Rheumatoid Arthritis
576. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
577. Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity
578. Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets
579. Updating the OMERACT Filter: Implications for Patient-reported Outcomes
580. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
581. Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis
582. Determining a Magnetic Resonance Imaging Inflammatory Activity Acceptable State Without Subsequent Radiographic Progression in Rheumatoid Arthritis: Results from a Followup MRI Study of 254 Patients in Clinical Remission or Low Disease Activity
583. Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis
584. Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
585. Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010
586. Drug-free gel containing ultra-deformable phospholipid vesicles (TDT 064) as topical therapy for the treatment of pain associated with osteoarthritis: a review of clinical efficacy and safety
587. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis : report from the Study Group for Risk Factors for Rheumatoid Arthritis
588. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
589. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis
590. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression
591. Tenosynovitis of the extensor carpi ulnaris tendon predicts erosive progression in early rheumatoid arthritis
592. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
593. Seropositivity and response to RTX: Data from the CERERRA collaboration.
594. Efficacy of different doses of rituximab for the treatment of rheumatoid arthritis: Data from the CERERRA collaboration.
595. Early versus delayed retreatment with rituximab (RTX) in relation to long term clinical response - Data from the CERERRA collaboration.
596. Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state
597. Characterization of long-term responders to first treatment course of rituximab (RTX) - Results from the CERERRA collaboration.
598. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
599. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients
600. COLABORADORES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.